Hippo Signaling Pathway
Ikena Oncology Cuts Hippo Pathway Inhibitor, Lays Off Half of Staff in Strategic Reprioritization
Ikena Oncology, Hippo pathway inhibitor, TEAD1-selective, layoffs, strategic update, biotech industry, clinical trials, cancer treatment